Menu

Top Stories

Published on Thursday, April 11, 2019

Moderated discussion: “Advancing the innovation ecosystem: Working together for patients,” in Washington, DC

Moderated discussion: “Advancing the innovation ecosystem: Working together for patients,” in Washington, DC

On April 3, 2019, Francis Collins, MD, PhD, director of the National Institutes of Health (NIH), Mikael Dolsten, MD, PhD, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer, joined in a discussion led by Susan Dentzer, visiting fellow at the Robert J. Margolis Center for Health Policy, Duke University, in Washington DC.

Photo: Francis Collins, MD, PhD, director of the NIH (left) and author Alejandro Hernandez, editorial manager of the Alpha-1 Foundation (right)

For 60 minutes, Collins, Dolsten, and Dentzer engaged in a conversation with the theme of: “Advancing the innovation ecosystem: working together for patients,” where they emphasized the need for continued collaboration between the private and public sectors, along with the patient community, in order to advance new and emerging technologies and innovative approaches for potentially life-saving treatments and new outcomes in medicine.

“We are currently living in remarkable times with amazing things happening in areas such as cancer immuno-therapy, gene therapy, and gene editing. The things that are happening right now, I had no idea they would even be possible just five or six years ago,” expressed Collins when asked about the current position “the ecosystem,” as they described the collaboration between the private and public sectors with small biotech companies; an ecosystem with symbiotic characteristics where all contributors play an important role in a tremendous team effort, in medical research.

Collins and Dolsten agreed on the importance of advocacy groups and organizations as well as the patient community, in being part of the process for better outcomes and the ability to bring new and potential treatments for various conditions to the clinic, including rare diseases, such as Alpha-1 Antitrypsin Deficiency (Alpha-1). 

“We need you, the patient community, you are the reason we have gotten this far,” said Collins.

“One of the most important resources needed for this ecosystem to strive is you, the patient. We need to line-up our resources and keep the ecosystem going, including the patient community. There is no one better to bring together what others (physicians) can do than patients: you inspire all of us,” expressed Dolsten.

The Alpha-1 Foundation applauds and supports these types of initiatives, in which patients become partners and are of vital importance for therapeutic development. 

The panel also mentioned that it is critical to spread awareness and education in the medical community, and being able to have early diagnosis and detection, while mentioning the Accelerating Medicines Partnership (AMP), a public-private partnership between the NIH, the U.S. Food and Drug Administration (FDA), multiple biopharmaceutical, and life science companies, as well as non-profit organizations to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets for therapeutics.

The ultimate goal of AMP is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them.

“Patient participation is critical for AMP, especially to remind us what we are doing and why-and-who we are doing it for,” said Collins, who also mentioned the Foundation for the National Institutes of Health (FNIH) as being instrumental in bringing together funds and resources from both the private and public sectors, to work in mutual collaboration in research projects that will ultimately benefit the patient community.

The Alpha-1 Foundation applauds these types of initiatives that support research and bring innovative approaches to the table for the benefit of the patient community, as we are committed to finding a cure for Alpha-1 and improving the lives of Alphas, and those affected by the condition, worldwide.

For more information, please visit the Collaboration Ecosystem website and the AMP website.


Print

Living donor saved her own son’s life

Tuesday, July 31, 2018
Dara Kass is an emergency physician in New York, but she did not need to be a doctor to know that something was going on with the third child, Sammy. At birth, the baby was smaller than his two siblings. He barely grew and was lethargic; his skin...
Divider

The Assistance Fund opens new program for Alphas

Monday, July 30, 2018
The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, announced the launch of a new program for individuals with Alpha-1 Antitrypsin Deficiency...
Divider

Alpha-1 Foundation board has new Chair

Friday, July 27, 2018
The Alpha-1 Foundation has the honor to announce that Jeanine D’Armiento, MD, PhD, has been named as the newest Chair of its board of directors. D’Armiento has served on the Foundation’s board since 2011, and before that, she had...
Divider

FDA warns of imposters sending consumers fake warning letters

Thursday, July 19, 2018
The U.S. Food and Drug Administration (FDA) is warning consumers about criminals forging FDA warning letters to target individuals who tried to purchase medicines online or over the phone. Based on the agency’s experience with criminals...
Divider

Inhaled alpha-1 antitrypsin: Kamada receives positive advice on new Phase 3 study design

Tuesday, July 17, 2018
Kamada Ltd., a plasma-derived protein therapeutics company, announced that it has received positive scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), related to the development...
Divider

FDA announces recall of several medicines containing valsartan

Monday, July 16, 2018
The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals and patients of a voluntary recall of several drug products containing the active ingredient valsartan, used to treat high blood pressure and heart failure. This...
Divider

New working group for patient advocacy is created

Monday, July 16, 2018
The Food and Drug Administration (FDA) and the Clinical Trials Transformation Initiative (CTTI) announced newly selected representatives for the Patient Engagement Collaborative (PEC), a joint endeavor originally disclosed in December 2017 to...
Divider

Jonathan Maidment’s journey continues to develop

Tuesday, July 10, 2018
Jonathan Maidment, the 23-year old Alpha who undertook the challenge of doing a hike-thru of the entire 2,600-mile Pacific Coast Trail (PCT), from Southern California to the border between Washington state and Canada, interrupted his journey for...
Divider

CRISPR gene editing may correct Alpha-1 but perhaps it is too soon

Friday, July 6, 2018
Groundbreaking research shows that CRISPR-Cas9 genome editing technology can correct the gene mutation responsible for Alpha-1 Antitrypsin Deficiency (Alpha-1), by successfully making a targeted gene correction in the livers of affected mice that...
Divider

Tips for enjoying fireworks while living with Alpha-1 lung disease

Tuesday, July 3, 2018
Holidays are happy occasions, filled with celebrations with family and friends. The 4th of July usually includes barbecues, pool parties or beach trips. But if you or a loved one has Alpha-1, holidays can be daunting. The change of routine, the...
Divider

The 27th National Education Conference opens with a panel on the latest Alpha-1 findings

Friday, June 29, 2018
The 27th Annual Alpha-1 National Education Conference, organized by the Alpha-1 Foundation in San Francisco, California, will open this Friday, June 29th with a panel discussion about the latest therapies and tools in Alpha-1. The session will be...
Divider

The 27th Annual National Education Conference will be streaming online

Thursday, June 28, 2018
The 27th Annual Alpha-1 National Education Conference is the largest annual gathering of Alphas, their families, leading healthcare professionals and industry in the world. It is a three-day event with educational programs given by national...
Divider
First45678910111213Last

Article Search

Enter keywords in text box and click Search button for results.

Archive